Neurology
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 1–12 of 13 articles
Quick answer
NovaPharmaNews Neurology hub for NMPA covers 13 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Lunai Bioworks Raises $20 Million to Acquire CNS Drug Delivery Technology for Alzheimer's Treatment
FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+
Keenova Therapeutics Presents New TERLIVAZ Clinical Data for Hepatorenal Syndrome at Digestive Disease Week 2026
Axoft Raises $55M Series A to Advance Brain-Computer Interface Clinical Trials Globally
Arcera Life Sciences Partners with Fosun Pharma for Neurodegenerative Disease R&D Collaboration
Immunic Appoints Dr. Michael Panzara as Chief Medical Officer to Lead Vidofludimus Calcium Development
Daewoong Pharmaceutical NABOTA Master Class Highlights PrabotulinumtoxinA Safety for High-Dose Treatments
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
SynSmart and Amporin Partner to Develop Small Molecule Therapeutics for Degenerative Diseases
P&G Health Launches First APAC Pharmacist Guidelines for Peripheral Neuropathy Management
Phantom Neuro Receives Approval for First Human Trial of Phantom X Neural Interface System
XellSmart Advances XS411 Parkinson's Cell Therapy to Phase II Trial After Positive Phase I Results
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.